Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

David E. Avigan, M.D.

Co-Author

Back to Details
This page shows the publications co-authored by David Avigan and Donald Kufe.
David Avigan
Connection Strength
6.371
Donald Kufe
  1. Dendritic/tumor fusion cells as cancer vaccines. Semin Oncol. 2012 Jun; 39(3):287-95.
    View in: PubMed
    Score: 0.504
  2. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res. 2004 Jul 15; 10(14):4699-708.
    View in: PubMed
    Score: 0.292
  3. Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia model. Haematologica. 2021 05 01; 106(5):1330-1342.
    View in: PubMed
    Score: 0.234
  4. Immune reconstitution following high-dose chemotherapy with stem cell rescue in patients with advanced breast cancer. Bone Marrow Transplant. 2000 Jul; 26(2):169-76.
    View in: PubMed
    Score: 0.220
  5. Selective in vivo mobilization with granulocyte macrophage colony-stimulating factor (GM-CSF)/granulocyte-CSF as compared to G-CSF alone of dendritic cell progenitors from peripheral blood progenitor cells in patients with advanced breast cancer undergoing autologous transplantation. Clin Cancer Res. 1999 Oct; 5(10):2735-41.
    View in: PubMed
    Score: 0.209
  6. Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine. Br J Haematol. 2019 05; 185(4):679-690.
    View in: PubMed
    Score: 0.201
  7. MUC1-C drives myeloid leukaemogenesis and resistance to treatment by a survivin-mediated mechanism. J Cell Mol Med. 2018 Aug; 22(8):3887-3898.
    View in: PubMed
    Score: 0.190
  8. Targeting MUC1-C suppresses polycomb repressive complex 1 in multiple myeloma. Oncotarget. 2017 Sep 19; 8(41):69237-69249.
    View in: PubMed
    Score: 0.180
  9. Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma. Mol Cancer Ther. 2017 10; 16(10):2304-2314.
    View in: PubMed
    Score: 0.180
  10. MUC1-C is a target in lenalidomide resistant multiple myeloma. Br J Haematol. 2017 09; 178(6):914-926.
    View in: PubMed
    Score: 0.179
  11. MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs. Leukemia. 2017 12; 31(12):2780-2790.
    View in: PubMed
    Score: 0.178
  12. MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia. Blood. 2017 Mar 30; 129(13):1791-1801.
    View in: PubMed
    Score: 0.174
  13. Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1. Br J Haematol. 2017 03; 176(6):929-938.
    View in: PubMed
    Score: 0.174
  14. Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions. Sci Transl Med. 2016 12 07; 8(368):368ra171.
    View in: PubMed
    Score: 0.172
  15. MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia. Oncotarget. 2016 Jun 28; 7(26):38974-38987.
    View in: PubMed
    Score: 0.167
  16. MUC1 in hematological malignancies. Leuk Lymphoma. 2016 11; 57(11):2489-98.
    View in: PubMed
    Score: 0.167
  17. MUC1-C drives MYC in multiple myeloma. Blood. 2016 05 26; 127(21):2587-97.
    View in: PubMed
    Score: 0.163
  18. Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma. Blood. 2015 Jul 16; 126(3):354-62.
    View in: PubMed
    Score: 0.155
  19. Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death. Blood. 2014 May 08; 123(19):2997-3006.
    View in: PubMed
    Score: 0.142
  20. MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells. Cancer Res. 2013 Sep 01; 73(17):5569-79.
    View in: PubMed
    Score: 0.136
  21. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res. 2013 Jul 01; 19(13):3640-8.
    View in: PubMed
    Score: 0.135
  22. Induction of antitumor immunity ex vivo using dendritic cells transduced with fowl pox vector expressing MUC1, CEA, and a triad of costimulatory molecules (rF-PANVAC). J Immunother. 2012 Sep; 35(7):555-69.
    View in: PubMed
    Score: 0.128
  23. Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol Immunother. 2013 Jan; 62(1):39-49.
    View in: PubMed
    Score: 0.126
  24. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother. 2011 Jun; 34(5):409-18.
    View in: PubMed
    Score: 0.117
  25. MUC1-C oncoprotein suppresses reactive oxygen species-induced terminal differentiation of acute myelogenous leukemia cells. Blood. 2011 May 05; 117(18):4863-70.
    View in: PubMed
    Score: 0.116
  26. Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood. 2011 Jan 13; 117(2):393-402.
    View in: PubMed
    Score: 0.113
  27. Terminal differentiation of chronic myelogenous leukemia cells is induced by targeting of the MUC1-C oncoprotein. Cancer Biol Ther. 2010 Sep 01; 10(5):483-91.
    View in: PubMed
    Score: 0.112
  28. Survival of human multiple myeloma cells is dependent on MUC1 C-terminal transmembrane subunit oncoprotein function. Mol Pharmacol. 2010 Aug; 78(2):166-74.
    View in: PubMed
    Score: 0.109
  29. Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28. J Immunother. 2010 Feb-Mar; 33(2):155-66.
    View in: PubMed
    Score: 0.107
  30. Immunomodulatory effects of vitamin D: implications for GVHD. Bone Marrow Transplant. 2010 Sep; 45(9):1463-8.
    View in: PubMed
    Score: 0.107
  31. Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer Res. 2009 Jun 15; 69(12):5133-41.
    View in: PubMed
    Score: 0.102
  32. Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cells. J Immunol. 2008 Jul 01; 181(1):808-21.
    View in: PubMed
    Score: 0.096
  33. Immunologic effects of sunitinib in renal cell carcinoma. J Clin Oncol. 2008 May 20; 26(15_suppl):14551.
    View in: PubMed
    Score: 0.095
  34. MUC1 oncoprotein regulates Bcr-Abl stability and pathogenesis in chronic myelogenous leukemia cells. Cancer Res. 2007 Dec 15; 67(24):11576-84.
    View in: PubMed
    Score: 0.092
  35. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother. 2007 Oct; 30(7):749-61.
    View in: PubMed
    Score: 0.091
  36. A novel isocoumarin derivative induces mitotic phase arrest and apoptosis of human multiple myeloma cells. Cancer Chemother Pharmacol. 2007 Feb; 59(3):329-35.
    View in: PubMed
    Score: 0.084
  37. Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation. Br J Haematol. 2005 Jun; 129(5):687-700.
    View in: PubMed
    Score: 0.077
  38. Dendritic cell fusion vaccines for cancer immunotherapy. Expert Opin Biol Ther. 2005 May; 5(5):703-15.
    View in: PubMed
    Score: 0.077
  39. Dendritic cells induce MUC1 expression and polarization on human T cells by an IL-7-dependent mechanism. J Immunol. 2005 Feb 15; 174(4):2376-86.
    View in: PubMed
    Score: 0.076
  40. Interim safety and efficacy results from a phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Clin Oncol. 2004 Jul 15; 22(14_suppl):2526.
    View in: PubMed
    Score: 0.073
  41. Update on cancer vaccines. Curr Opin Gastroenterol. 2002 Nov; 18(6):723-31.
    View in: PubMed
    Score: 0.065
  42. Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. Blood. 2002 Apr 01; 99(7):2512-7.
    View in: PubMed
    Score: 0.062
  43. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J Immunol. 2000 Aug 01; 165(3):1705-11.
    View in: PubMed
    Score: 0.055
  44. Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc Natl Acad Sci U S A. 2000 Mar 14; 97(6):2715-8.
    View in: PubMed
    Score: 0.054
  45. MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells. Blood. 2014 Jan 30; 123(5):734-42.
    View in: PubMed
    Score: 0.035
  46. Induction of anti-leukemic cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous myeloblasts. Leuk Res. 2004 Dec; 28(12):1303-12.
    View in: PubMed
    Score: 0.019
  47. Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. Br J Haematol. 2004 May; 125(3):343-52.
    View in: PubMed
    Score: 0.018
  48. Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpesvirus gene sequences. Blood. 1999 Mar 01; 93(5):1487-95.
    View in: PubMed
    Score: 0.013
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.